{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:40:38Z","timestamp":1790984438661,"version":"4.1.0"},"reference-count":20,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although heparin-induced thrombocytopenia (HIT) is a known complication of intravenous unfractionated heparin (UFH), its incidence in medical patients treated with subcutaneous UFH is less well defined. To determine the incidence of HIT in this category of patients, the platelet count was performed at baseline and then every 3\u2009\u00b1\u20091 days in 598 consecutive patients admitted to 2 medical wards and treated with subcutaneous UFH for prophylactic (n\u2009=\u2009360) or therapeutic (n\u2009=\u2009238) indications. The diagnosis of HIT was accepted in the case of a platelet drop of 50% or more and either the demonstration of heparin-dependent antibodies or (when this search could not be performed) the combination of the following features: (1) the absence of any other obvious clinical explanation for thrombocytopenia, (2) the occurrence of thrombocytopenia at least 5 days after heparin start, and (3) either the normalization of the platelet count within 10 days after heparin discontinuation or the earlier patient's death due to an unexpected thromboembolic complication. HIT developed in 5 patients (0.8%; 95% CI, 0.1%-1.6%); all of them belonged to the subgroup of patients who received heparin for prophylactic indications. The prevalence of thromboembolic complications in patients with HIT (60%) was remarkably higher than that observed in the remaining 593 patients (3.5%), leading to an odds ratio of 40.8 (95% CI, 5.2-162.8). Although the frequency of HIT in hospitalized medical patients treated with subcutaneous heparin is lower than that observed in other clinical settings, this complication is associated with a similarly high rate of thromboembolic events.<\/jats:p>","DOI":"10.1182\/blood-2002-07-2201","type":"journal-article","created":{"date-parts":[[2003,4,2]],"date-time":"2003-04-02T13:43:59Z","timestamp":1049291039000},"page":"2955-2959","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":216,"title":["The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study"],"prefix":"10.1182","volume":"101","author":[{"given":"Bruno","family":"Girolami","sequence":"first","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Prandoni","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero M.","family":"Stefani","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Tanduo","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Sabbion","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Eichler","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ramon","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannella","family":"Baggio","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Fabris","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Girolami","sequence":"additional","affiliation":[{"name":"From the Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy; and Institute for Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111617253060100_B1","first-page":"409","article-title":"Heparin induced thrombocytopenia with thrombotic and hemorrhagic manifestations.","volume":"136","author":"Rhodes","year":"1973","journal-title":"Surg Gynecol Obstet."},{"key":"2019111617253060100_B2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJM197607292950501","article-title":"Heparin-induced immune thrombocytopenia.","volume":"295","author":"Babcock","year":"1976","journal-title":"N Engl J Med."},{"key":"2019111617253060100_B3","doi-asserted-by":"crossref","first-page":"13301335","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.","volume":"332","author":"Warkentin","year":"1995","journal-title":"N Engl J Med."},{"key":"2019111617253060100_B4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","article-title":"Impact of the patient population on the risk for heparin-induced thrombocytopenia.","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood."},{"key":"2019111617253060100_B5","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJM200104263441704","article-title":"Temporal aspects of heparin-induced thrombocytopenia.","volume":"344","author":"Warkentin","year":"2001","journal-title":"N Engl J Med."},{"key":"2019111617253060100_B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0038-1656329","article-title":"Platelet Factor 4 complexed to heparin is the target for antibodies in heparin-induced thrombocytopenia.","volume":"68","author":"Amiral","year":"1992","journal-title":"Thromb Haemost."},{"key":"2019111617253060100_B7","first-page":"247","article-title":"Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.","volume":"71","author":"Greinacher","year":"1994","journal-title":"Thromb Haemost."},{"key":"2019111617253060100_B8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI116987","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.","volume":"93","author":"Visentin","year":"1994","journal-title":"J Clin Invest."},{"key":"2019111617253060100_B9","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4.","volume":"83","author":"Kelton","year":"1994","journal-title":"Blood."},{"key":"2019111617253060100_B10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood.V96.3.846","article-title":"Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range.","volume":"96","author":"Greinacher","year":"2000","journal-title":"Blood."},{"key":"2019111617253060100_B11","first-page":"9","article-title":"Clinical presentation of heparin-induced thrombocytopenia.","volume":"35(suppl 5)","author":"Warkentin","year":"1998","journal-title":"Semin Hematol."},{"key":"2019111617253060100_B12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1445-5994.1992.tb02796.x","article-title":"Heparin induced thrombocytopenia.","volume":"22","author":"Chong","year":"1992","journal-title":"Aust N Z J Med."},{"key":"2019111617253060100_B13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00000441-199304000-00003","article-title":"Heparin-associated thrombocytopenia: a critical review and pooled analysis.","volume":"305","author":"Schmitt","year":"1993","journal-title":"Am J Med Sci."},{"key":"2019111617253060100_B14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1027381103184","article-title":"Laboratory testing for heparin-induced thrombocytopenia.","volume":"10","author":"Warkentin","year":"2001","journal-title":"J Thromb Thrombolysis."},{"key":"2019111617253060100_B15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1055\/s-0037-1614536","article-title":"First workshop for the detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with PF4\/heparin ELISA.","volume":"81","author":"Eichler","year":"1999","journal-title":"Thromb Haemost."},{"key":"2019111617253060100_B16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1378\/chest.119.1_suppl.132S","article-title":"Prevention of venous thromboembolism.","volume":"119(suppl)","author":"Geerts","year":"2001","journal-title":"Chest."},{"key":"2019111617253060100_B17","first-page":"78","article-title":"The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.","volume":"21","author":"Caprini","year":"2002","journal-title":"Int Angiol."},{"key":"2019111617253060100_B18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.","volume":"119(suppl)","author":"Hirsh","year":"2001","journal-title":"Chest."},{"key":"2019111617253060100_B19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-136-3-200202050-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia.","volume":"136","author":"Rice","year":"2002","journal-title":"Ann Intern Med."},{"key":"2019111617253060100_B20","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-135-7-200110020-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia and thrombosis.","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/8\/2955\/1266769\/h80803002955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/8\/2955\/1266769\/h80803002955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T17:25:40Z","timestamp":1573925140000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/8\/2955\/16842\/The-incidence-of-heparininduced-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,15]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-07-2201","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4,15]]}}}